Cancer Family
Gastric Neoplasm
CI-CAN-00000185Explore in graph →
Non-malignant720 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000185Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04348643 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07283848 | Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT05678205 |
| A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors |
| withdrawn |
| Phase 1 / Phase 2 |
| 0 |
| Artiva Biotherapeutics, Inc.INDUSTRY |
| 2 |
| Jul 30, 2025 |
| clinicaltrials |
| NCT04180761 | Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer(ProPeC) | withdrawn | Phase 2 | 0 | University Hospital TuebingenOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT04976660 | TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Tarus Therapeutics, Inc.INDUSTRY | 0 | Mar 18, 2025 | clinicaltrials |
| NCT04863430 | Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach | withdrawn | Phase 2 | 0 | Peking UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05703555 | INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701(INTRUSION) | withdrawn | Phase 2 | 0 | Erasmus Medical CenterOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT05411679 | EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Ellipses PharmaINDUSTRY | 3 | Jun 12, 2023 | clinicaltrials |
| NCT02344810 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors(MATILDA) | withdrawn | Phase 2 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT05181865 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Flame BiosciencesINDUSTRY | 0 | Feb 7, 2022 | clinicaltrials |
| NCT04105062 | LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery | withdrawn | Phase 1 / Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Dec 9, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT03554395 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03739801 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT03766607 | Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer | withdrawn | Phase 2 | 0 | Korean South West Oncology GroupNETWORK | 1 | Sep 19, 2019 | clinicaltrials |
| NCT00387530 | Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 1 | Aug 2, 2019 | clinicaltrials |
| NCT02943603 | A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach | withdrawn | Phase 2 | 0 | Weijing Sun, MD, FACPOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT00800969 | Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach | withdrawn | Phase 2 | 0 | University of ZurichOTHER | 1 | Jun 23, 2016 | clinicaltrials |
| NCT00620607 | huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas | withdrawn | Phase 2 | 0 | ImmunoGen, Inc.INDUSTRY | 1 | Aug 26, 2015 | clinicaltrials |
| NCT01070290 | A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen | withdrawn | Phase 2 | 0 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 0 | Jan 7, 2014 | clinicaltrials |
| NCT00209612 | Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC. | withdrawn | Phase 1 / Phase 2 | 40 | Hokkaido Gastrointestinal Cancer Study GroupOTHER | 1 | Feb 17, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Jul 10, 2026source: clinicaltrials